Actual possibilities and perspectives of biological drugs in treatment of systemic vasculitides. III. Biological drugs in giant cell arteritis
Revmatologiia (Bulgaria) · 2021
DOI: 10.35465/29.1.2020.pp8-20 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revmatologiia (Bulgaria), 2021. Verfasst von D. Dimov. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
A review of the literary data about the hitherto exiting investigations on biological drugs (BDs) as an alternative of the corticosteroids (CSs) – the current basal therapy of giant cell arteritis (GCA) is presented. The TNF-alpha-inhibitors are already definitely discarded on the account of their inefficiency and inadequate tolerability. The favorable initial results of BDs against IL-1, CTLA4-iGg1 and especially IL-12/23 should receive a reliable assessment after completion of the additional large-scale investigations. Indisputably only the data on efficacy of tocilizumab (anti-IL-6) for induction and maintenance of GCA remission and its marked CS-saving effect are convincing. Reasonably, TCM received a permission for use as adjunctive therapy in the management of GCA.
Zitieren
APA
Dimov, D. (2021). Actual possibilities and perspectives of biological drugs in treatment of systemic vasculitides. III. Biological drugs in giant cell arteritis. Revmatologiia (Bulgaria). https://doi.org/10.35465/29.1.2020.pp8-20
Vancouver
Dimov D. Actual possibilities and perspectives of biological drugs in treatment of systemic vasculitides. III. Biological drugs in giant cell arteritis. Revmatologiia (Bulgaria). 2021. doi:10.35465/29.1.2020.pp8-20
BibTeX
@article{Dimov2021,
author = {Dimov, D.},
title = {Actual possibilities and perspectives of biological drugs in treatment of systemic vasculitides. III. Biological drugs in giant cell arteritis},
journal = {Revmatologiia (Bulgaria)},
year = {2021},
doi = {10.35465/29.1.2020.pp8-20}
}
EUVIMED